Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Cluster-randomized, Open-label, Clinical Trial to Study the Safety and Efficacy of Ivermectin Mass Drug Administration to Reduce Malaria Transmission in Two African Settings

NCT04966702 is registered in ClinicalTrials.gov with Barcelona Institute for Global Health as lead sponsor.

NCT NCT04966702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Cluster-randomized, Open-label, Clinical Trial to Study the Safety and Efficacy of Ivermectin Mass Drug Administration to Reduce Malaria Transmission in Two African Settings
Lead sponsor
Barcelona Institute for Global Health
Phase
Phase 3
Overall status
Completed
Start date
March 17, 2022
Completion date
October 3, 2024
Enrollment
48,145 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria